ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2026
Seroprevalence of Helicobacter pylori Infection Among Asymptomatic Patients Served by a Safety-Net Healthcare System.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers.International journal of cancer · 2026Article
- Prevalence of Gastric Intestinal Metaplasia Among Patients with Active Helicobacter Pylori Infection Served by a Safety-Net Healthcare System.Digestive diseases and sciences · 2026Article
- Characteristics and Incidence of Gastric Cancer Among Patients with Autoimmune and Non-autoimmune Atrophic Gastritis in a U.S. Population.Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
Abstract
BACKGROUND &
aimsHelicobacter pylori screening and eradication is a cost-effective strategy for primary gastric cancer prevention in high-risk populations outside the United States. There is a paucity of population-based H pylori seroprevalence data available in high-risk U.S. groups, particularly data for low-income, uninsured patient populations.
methodsWe used data from a cross-sectional study of a largely underserved, immigrant, and minority patient population. Inclusion criteria included asymptomatic individuals 30-65 years of age without prior H pylori testing or treatment. Consented patients completed a study survey and a blood draw to screen for H pylori using IgG serology. We calculated seroprevalence overall and within subgroups of the study population.
resultsScreening for H pylori infection was completed in 1021 individuals. Participants had a mean age of 47.5 years and were 69.9% female, and 88.7% were Hispanic individuals. Overall, 63.9% (95% confidence interval [CI], 60.9%-66.8%) of participants were seropositive for H pylori. H pylori seroprevalence was similar across age groups but was higher among males (69.1%; 95% CI, 63.9%-74.2%) than females (61.6%; 95% CI, 58.1%-65.2%). Seroprevalence of H pylori was highest for Hispanic (65.9%; 95% CI, 62.8%-69.0%) and lowest for non-Hispanic White (45.0%; 95% CI, 23.2%-66.8%) individuals. H pylori seroprevalence was highest among individuals born in Central America (75.1%). Risk for infection was no different between second- and third-generation immigrants.
conclusionsIn this population-based study, almost two-thirds of asymptomatic patients were seropositive for H pylori. Prevalence was over 40% among all subgroups. Screening solely based on race and ethnicity may inadvertently exacerbate disparities by overlooking confounding factors for infection like low socioeconomic status and regional exposures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.